tiprankstipranks
Trending News
More News >
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
US Market
Advertisement

Janux Therapeutics Inc (JANX) Stock Forecast & Price Target

Compare
420 Followers
See the Price Targets and Ratings of:

JANX Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Janux
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JANX Stock 12 Month Forecast

Average Price Target

$81.00
▲(243.80%Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Janux Therapeutics Inc in the last 3 months. The average price target is $81.00 with a high forecast of $200.00 and a low forecast of $25.00. The average price target represents a 243.80% change from the last price of $23.56.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","201":"$201","66.75":"$66.8","111.5":"$111.5","156.25":"$156.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$81.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,66.75,111.5,156.25,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.22,36.818461538461534,50.41692307692308,64.01538461538462,77.61384615384615,91.21230769230769,104.81076923076924,118.40923076923077,132.0076923076923,145.60615384615386,159.20461538461538,172.80307692307693,186.40153846153848,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.22,27.664615384615384,32.10923076923077,36.55384615384615,40.99846153846154,45.44307692307692,49.887692307692305,54.332307692307694,58.776923076923076,63.22153846153846,67.66615384615385,72.11076923076922,76.55538461538461,{"y":81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.22,23.356923076923074,23.493846153846153,23.63076923076923,23.767692307692307,23.904615384615383,24.04153846153846,24.178461538461537,24.315384615384616,24.45230769230769,24.58923076923077,24.726153846153846,24.863076923076925,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.19,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$200.00Average Price Target$81.00Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on JANX
TipRanks AITipRanks
Not Ranked
TipRanks
$26
Hold
10.36%
Upside
Reiterated
07/26/25
The overall stock score of Janux Therapeutics Inc is primarily influenced by its financial performance, characterized by strong revenue growth but offset by profitability challenges and reliance on financing. Technical analysis shows positive short-term momentum, although longer-term trends are weak. Valuation remains a concern due to negative earnings. The lack of dividend yield also limits immediate shareholder returns.
TD Cowen Analyst forecast on JANX
Marc FrahmTD Cowen
TD Cowen
Buy
Reiterated
07/28/25
TD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)
H.C. Wainwright Analyst forecast on JANX
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$70
Buy
197.11%
Upside
Reiterated
07/28/25
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX)
JonesTrading Analyst forecast on JANX
Soumit RoyJonesTrading
JonesTrading
$90
Buy
282.00%
Upside
Reiterated
07/28/25
Janux Therapeutics: Strategic Innovations and Robust Pipeline Drive Buy Rating
UBS Analyst forecast on JANX
Unknown AnalystUBS
Not Ranked
UBS
$69$65
Buy
175.89%
Upside
Reiterated
07/28/25
UBS Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)
Cantor Fitzgerald Analyst forecast on JANX
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$200
Buy
748.90%
Upside
Reiterated
07/25/25
Janux Therapeutics Inc (JANX) Receives a Buy from Cantor Fitzgerald
LifeSci Capital Analyst forecast on JANX
Oliver McCammonLifeSci Capital
LifeSci Capital
$100
Buy
324.45%
Upside
Reiterated
07/25/25
Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating
Scotiabank Analyst forecast on JANX
George FarmerScotiabank
Scotiabank
$36
Hold
52.80%
Upside
Reiterated
07/25/25
Scotiabank Remains a Hold on Janux Therapeutics Inc (JANX)
Bank of America Securities Analyst forecast on JANX
Alec StranahanBank of America Securities
Bank of America Securities
$64
Buy
171.65%
Upside
Reiterated
07/25/25
Janux Therapeutics' Strategic Expansion and Promising Pipeline Drive Buy Rating
William Blair Analyst forecast on JANX
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
07/25/25
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics
Evercore ISI Analyst forecast on JANX
Jonathan MillerEvercore ISI
Evercore ISI
$25
Buy
6.11%
Upside
Reiterated
07/25/25
Janux Therapeutics Inc (JANX) Gets a Buy from Evercore ISI
Leerink Partners Analyst forecast on JANX
Jeffrey La RosaLeerink Partners
Leerink Partners
Buy
Reiterated
07/25/25
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification
Raymond James Analyst forecast on JANX
Sean McCutcheonRaymond James
Raymond James
$65
Buy
175.89%
Upside
Initiated
07/11/25
Janux Therapeutics initiated with an Outperform at Raymond JamesJanux Therapeutics initiated with an Outperform at Raymond James
BTIG
$100
Buy
324.45%
Upside
Reiterated
05/09/25
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (NASDAQ: TBPH), Immunocore Holdings (NASDAQ: IMCR) and Janux Therapeutics Inc (NASDAQ: JANX)
Wedbush
$76
Buy
222.58%
Upside
Reiterated
05/09/25
Janux Therapeutics Inc (JANX) Has a New Rating from Wedbush
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on JANX
TipRanks AITipRanks
Not Ranked
TipRanks
$26
Hold
10.36%
Upside
Reiterated
07/26/25
The overall stock score of Janux Therapeutics Inc is primarily influenced by its financial performance, characterized by strong revenue growth but offset by profitability challenges and reliance on financing. Technical analysis shows positive short-term momentum, although longer-term trends are weak. Valuation remains a concern due to negative earnings. The lack of dividend yield also limits immediate shareholder returns.
TD Cowen Analyst forecast on JANX
Marc FrahmTD Cowen
TD Cowen
Buy
Reiterated
07/28/25
TD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)
H.C. Wainwright Analyst forecast on JANX
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$70
Buy
197.11%
Upside
Reiterated
07/28/25
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX)
JonesTrading Analyst forecast on JANX
Soumit RoyJonesTrading
JonesTrading
$90
Buy
282.00%
Upside
Reiterated
07/28/25
Janux Therapeutics: Strategic Innovations and Robust Pipeline Drive Buy Rating
UBS Analyst forecast on JANX
Unknown AnalystUBS
Not Ranked
UBS
$69$65
Buy
175.89%
Upside
Reiterated
07/28/25
UBS Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)
Cantor Fitzgerald Analyst forecast on JANX
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$200
Buy
748.90%
Upside
Reiterated
07/25/25
Janux Therapeutics Inc (JANX) Receives a Buy from Cantor Fitzgerald
LifeSci Capital Analyst forecast on JANX
Oliver McCammonLifeSci Capital
LifeSci Capital
$100
Buy
324.45%
Upside
Reiterated
07/25/25
Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating
Scotiabank Analyst forecast on JANX
George FarmerScotiabank
Scotiabank
$36
Hold
52.80%
Upside
Reiterated
07/25/25
Scotiabank Remains a Hold on Janux Therapeutics Inc (JANX)
Bank of America Securities Analyst forecast on JANX
Alec StranahanBank of America Securities
Bank of America Securities
$64
Buy
171.65%
Upside
Reiterated
07/25/25
Janux Therapeutics' Strategic Expansion and Promising Pipeline Drive Buy Rating
William Blair Analyst forecast on JANX
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
07/25/25
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics
Evercore ISI Analyst forecast on JANX
Jonathan MillerEvercore ISI
Evercore ISI
$25
Buy
6.11%
Upside
Reiterated
07/25/25
Janux Therapeutics Inc (JANX) Gets a Buy from Evercore ISI
Leerink Partners Analyst forecast on JANX
Jeffrey La RosaLeerink Partners
Leerink Partners
Buy
Reiterated
07/25/25
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification
Raymond James Analyst forecast on JANX
Sean McCutcheonRaymond James
Raymond James
$65
Buy
175.89%
Upside
Initiated
07/11/25
Janux Therapeutics initiated with an Outperform at Raymond JamesJanux Therapeutics initiated with an Outperform at Raymond James
BTIG
$100
Buy
324.45%
Upside
Reiterated
05/09/25
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (NASDAQ: TBPH), Immunocore Holdings (NASDAQ: IMCR) and Janux Therapeutics Inc (NASDAQ: JANX)
Wedbush
$76
Buy
222.58%
Upside
Reiterated
05/09/25
Janux Therapeutics Inc (JANX) Has a New Rating from Wedbush
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Janux Therapeutics Inc

1 Month
xxx
Success Rate
5/11 ratings generated profit
45%
Average Return
+4.41%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of +4.41% per trade.
3 Months
xxx
Success Rate
3/8 ratings generated profit
38%
Average Return
-6.13%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of -6.13% per trade.
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
5/15 ratings generated profit
33%
Average Return
+74.76%
reiterated a buy rating 6 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +74.76% per trade.
2 Years
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
+32.68%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +32.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JANX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
May 25
Jun 25
Jul 25
Strong Buy
16
11
18
14
19
Buy
9
4
7
6
10
Hold
2
1
2
2
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
16
27
22
35
In the current month, JANX has received 29 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. JANX average Analyst price target in the past 3 months is 81.00.
Each month's total comprises the sum of three months' worth of ratings.

JANX Financial Forecast

JANX Earnings Forecast

Next quarter’s earnings estimate for JANX is -$0.46 with a range of -$0.69 to -$0.32. The previous quarter’s EPS was -$0.38. JANX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year JANX has Outperformed its overall industry.
Next quarter’s earnings estimate for JANX is -$0.46 with a range of -$0.69 to -$0.32. The previous quarter’s EPS was -$0.38. JANX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year JANX has Outperformed its overall industry.

JANX Sales Forecast

Next quarter’s sales forecast for JANX is $250.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. JANX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.11% of the time in the same period. In the last calendar year JANX has Outperformed its overall industry.
Next quarter’s sales forecast for JANX is $250.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. JANX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.11% of the time in the same period. In the last calendar year JANX has Outperformed its overall industry.

JANX Stock Forecast FAQ

What is JANX’s average 12-month price target, according to analysts?
Based on analyst ratings, Janux Therapeutics Inc’s 12-month average price target is 81.00.
    What is JANX’s upside potential, based on the analysts’ average price target?
    Janux Therapeutics Inc has 243.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JANX a Buy, Sell or Hold?
          Janux Therapeutics Inc has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Janux Therapeutics Inc’s price target?
            The average price target for Janux Therapeutics Inc is 81.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $200.00 ,the lowest forecast is $25.00. The average price target represents 243.80% Increase from the current price of $23.56.
              What do analysts say about Janux Therapeutics Inc?
              Janux Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of JANX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis